DTC
SYRE icon

Deep Track Capital’s Spyre Therapeutics SYRE Stock Holding History

Deep Track Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-219,015
Closed -$3.28M – 71
2025
Q2 		$3.28M Hold
219,015
– – 0.11% 59
2025
Q1 		$3.53M Hold
219,015
– – 0.11% 64
2024
Q4 		$5.1M Sell
219,015
-780,985
-78% -$22.9M 0.19% 57
2024
Q3 		$29.4M Sell
1,000,000
-756,667
-43% -$21.1M 0.93% 34
2024
Q2 		$41.3M Buy
1,756,667
+543,247
+45% +$18.3M 1.23% 32
2024
Q1 		$46M Sell
1,213,420
-739,340
-38% -$21.4M 1.32% 30
2023
Q4 		$42M Buy
+1,952,760
New +$26.9M 1.4% 31

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deep Track Capital's SYRE Position: Q3 2025 in Review

Deep Track Capital sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 219,015 shares — an estimated $3.28M sold.

Deep Track Capital first reported a position in SYRE in Q4 2023 and held it in 7 quarters. The position peaked at $46M in Q1 2024. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Deep Track Capital reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Deep Track Capital sold 219,015 Spyre Therapeutics shares in Q3 2025, an estimated $3.28M.
  • Deep Track Capital first reported a position in Spyre Therapeutics in Q4 2023 and held it in 7 quarters.
  • Deep Track Capital's Spyre Therapeutics position peaked at $46M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.